ZAPRINAST ACCELERATES RECOVERY FROM ESTABLISHED ACUTE-RENAL-FAILURE IN THE RAT

被引：40

作者：

GUAN, ZG ^{[1
]}

MILLER, SB ^{[1
]}

GREENWALD, JE ^{[1
]}

机构：

[1] WASHINGTON UNIV, SCH MED, DEPT MED MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA

来源：

KIDNEY INTERNATIONAL | 1995年 / 47卷 / 06期

关键词：

D O I：

10.1038/ki.1995.220

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Atrial natriuretic factor (ANF) has been demonstrated to be effective in the treatment of acute renal failure (ARF) in both rat and humans. The biological effects of ANF are presumed to be mediated by the generation of intracellular 3',5'-cyclic guanosine monophosphate (cGMP). Therefore, the current investigation examined whether zaprinast (M&B 22948), a guanosine 3',5'-cyclic monophosphate (cGMP)-specific phosphodiesterase inhibitor, would be effective in the treatment of established acute renal failure in the rat. Acute renal failure was induced by 60 minutes of bilateral renal artery clamping. Twenty-four hours after the ischemic insult, rats received either vehicle (5% Dextrose), zaprinast (0.03 or 0.3 mg/kg/min) or ANF24 (0.2 mu g/kg/min) intravenously for four hours. Renal function, as measured by daily serum creatinine (days 1 to 7) and day 2 inulin clearances, was dramatically improved by zaprinast but not ANF treatment. Forty-eight hours post-renal ischemia, glomerular filtration rate (GFR) was 0.14 +/- 0.04 (ml/min/100 g body wt) in the vehicle and 0.94 +/- 0.29 in the zaprinast treated animals. To evaluate the mechanism by which zaprinast accelerated renal recovery, we measured regional blood flow in the postischemic rat kidneys during drug treatment with a laser doppler flowmeter. Both high and low dose zaprinast significantly increased cortical (17%) and outer medullary blood flow (40% and 60%), an effect not seen with ANF. In summary, zaprinast is effective in the treatment of established ischemic ARF. The mechanism by which zaprinast accelerates renal recovery is due to its unique ability to stimulate regional renal blood flow and increase intracellular cGMP in the setting of tissue ischemia.

引用

页码：1569 / 1575

页数：7

共 54 条

[21]

Leitman D.C., Agnost V.L., Tuan J.J., Andresen J.W., Murad F., Atrial natriuretic factor and sodium nitroprusside increase cyclic GMP in cultured rat lung fibroblasts by activating different forms of guanylate cyclase, J Biochem, 244, pp. 69-74, (1987)

[22]

Chintala M.S., Chiu P.J.S., Vemulapalli S., Watkins R.W., Sybertz E.J., Inhibition of endothelial derived relaxing factor (EDRF) aggravates ischemic acute renal failure in anesthetized rats, Naunyn-Schmiedeberg's Arch Pharmacol, 348, pp. 305-310, (1993)

[23]

Noguchi S., Kashihara Y., Ikegami Y., Morimoto K., Miyamoto M., Nakao K., Insulin-like growth factor-1 ameliorates transient ischemia-induced acute renal failure in rats, J Pharmacol Exp Ther, 267, pp. 919-926, (1993)

[24]

Thompsom W.J., Cyclic nucleotide phosphodiesterases: Pharmacology, biochemistry and function, Pharmac Ther, 51, pp. 13-33, (1991)

[25]

Weishaar R.E., Multiple molecular forms of phosphodiesterase: An overview, J Cyclic Nucl Protein Phosphorylation Res, 11, pp. 463-472, (1987)

[26]

Beavo J.A., Multiple isozymes of cyclic nucleotide phosphodiesterase, Adv Second Mesenger Phosphoprotein Res, 22, pp. 1-38, (1988)

[27]

Pang D.C., Cyclic AMP and cyclic GMP phosphodiesterases: Target for drug development, Drug Dev Res, 12, pp. 85-92, (1988)

[28]

Dundore R.L., Clas D.M., Wheeler L.T., Habeeb P.G., Bode D.C., Buchholz R.A., Sliver P.J., Pagani E.D., Zaprinast increases cyclic GMP levels in plasma and aortic tissue of rats, Eur J Pharmacol, 249, pp. 293-297, (1993)

[29]

Mcmahon E.G., Palomo M.A., Mehta P., Olins G.M., Depressor and natriuretic effects of M&B 22,948, a guanosine cyclic 3′,5′

[30]

-monophosphate-selective phosphodiesterase inhibitor, J Pharmacol Exp Ther, 251, pp. 1000-1005, (1989)

← 1 2 3 4 5 6 →